Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia (ITP)
Corticosteroids represent the standard of care in the first-line management of immune thrombocytopenia (ITP), but high relapse rates highlight a significant unmet medical need. Novel therapeutic approaches are warranted that achieve durable responses and reduce the need for toxic long-term corticosteroid use. Here, we compared the ability of the oral thrombopoietin receptor agonist eltrombopag (ETB) in combination with a short course of high-dose dexamethasone (dex) to induce sustained response off treatment in patients with newly diagnosed ITP versus 1-3 cycles of dex monotherapy.